Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HI-Bio Reports Positive Phase 2 Results of Felzartamab in Kidney Transplant Patients
Details : MOR202 (felzartamab) is an investigational monoclonal antibody designed to specifically target and deplete CD38+ cells. It is being evaluated for late AMR in kidney transplant recipients.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Inapplicable
May 25, 2024
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Biogen
Deal Size : $1,800.0 million
Deal Type : Acquisition
Biogen Expands Immunology Portfolio By Acquiring Human Immunology Biosciences
Details : Through acquisition, Biogen gains access to pipeline-in-a-product for immune-mediated diseases, including MOR202 (felzartamab) for treating primary membranous nephropathy.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : $1,150.0 million
May 22, 2024
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Biogen
Deal Size : $1,800.0 million
Deal Type : Acquisition
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Alpha Wave Global
Deal Size : $95.0 million
Deal Type : Series B Financing
HI-Bio Announces $95 Million Series B Financing for Targeted Therapies in Immune Diseases
Details : The net proceeds will be used to advance MOR202 (felzartamab), a monoclonal antibody targeting CD38, through clinical readouts in multiple indications and preparation for registrational studies.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Alpha Wave Global
Deal Size : $95.0 million
Deal Type : Series B Financing
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab in Kidney Transplants
Details : MOR202 (felzartamab) is an investigational monoclonal antibody targeting CD38, being evaluated for treating antibody-mediated rejection in kidney transplant recipients.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Inapplicable
March 21, 2024
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Biogen
Deal Size : $1,800.0 million
Deal Type : Acquisition
Biogen Completes Acquisition of Human Immunology Biosciences
Details : Through the acquisition, Biogen will have access to pipeline a range of immune-mediated diseases, including MOR202 (felzartamab), being evaluated for treating primary membranous nephropathy.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : $1,150.0 million
February 07, 2024
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Biogen
Deal Size : $1,800.0 million
Deal Type : Acquisition
Lead Product(s) : HIB210
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases
Details : HIB210 is an investigational therapeutic human monoclonal antibody directed against complement factor C5a receptor 1 (C5aR1). C5aR1 is responsible for guiding and activating myeloid cells and is highly expressed on neutrophils, monocytes and macrophages.
Product Name : HIB210
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : HIB210
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOR202 (felzartamab) is an investigational monoclonal antibody designed to deplete CD38+ plasma cells, which are believed to drive Primary Membranous Nephropathy (PMN) through the production of anti-PLA2R (aPLA2R) autoantibodies.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Inapplicable
November 04, 2023
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOR 202 (felzartamab) is a monoclonal antibody directed against CD38, it has the potential to deplete CD38+ plasma cells while leaving other functionally important plasma cells intact. it is under phase 2 clinical development for the treatment of PMN.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOR202 (felzartamab) is human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. In PMN, CD38+long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidn...
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Arch Ventures
Deal Size : $120.0 million
Deal Type : Financing
Details : The proceedings for the development of felzartamab (MOR202), an anti-CD38 antibody, and HIB210, an anti-C5aR1 antibody. HI-Bio is testing felzartamab for MN and IgAN, with the potential to be the best-in-class therapy for autoantibody diseases.
Product Name : MOR202
Product Type : Antibody
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Arch Ventures
Deal Size : $120.0 million
Deal Type : Financing